AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20646753 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 119
Study 20646753 — intervention group
Group type: COMPARATOR
Intervention: PQ1
Number of subjects: 119
Study 17668878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (80 mg/day)
Number of subjects: 326
Study 17668878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 16355489 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, faith-based weight loss intervention for 12 weeks
Number of subjects: 59
Study 16355489 — intervention group
Group type: COMPARATOR
Intervention: Culturally tailored weight loss intervention with no active faith component
Number of subjects: 59
Study 12196230 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedure
Number of subjects: 22
Study 12196230 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical procedure
Number of subjects: 22
Study 10682570 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 10682570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 10682570 — intervention group
Group type: COMPARATOR
Intervention: Control (Fentanyl)
Number of subjects: 30
Study 8665880 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam followed by vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study 8665880 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam followed by atracurium 0.5 mg kg‐1
Number of subjects: 30
Study 2667526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of luffa operculata D4, kalium bicromicum D4 and cinnabaris D3
Number of subjects: 152
Study 2667526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of kalium bicromicum D4 and cinnabaris D3
Number of subjects: 152
Study 2667526 — intervention group
Group type: EXPERIMENTAL
Intervention: Luffa operculata D4
Number of subjects: 152
Study 2667526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1002948 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 1002948 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 0
Study 1002948 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with behavior therapy
Number of subjects: 0
Study 1002948 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy and placebo
Number of subjects: 0
Study 30830727 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate 0.2 mg/d
Number of subjects: 166
Study 30830727 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate 0.4 mg/d
Number of subjects: 166
Study 30830727 — intervention group
Group type: COMPARATOR
Intervention: placebo/pemafibrate 0.2 mg/d
Number of subjects: 166
Study 28832217 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively adjusted Pain Catastrophizing Scale (PCS)
Number of subjects: 122
Study 28832217 — intervention group
Group type: COMPARATOR
Intervention: Standard Pain Catastrophizing Scale (PCS)
Number of subjects: 122
Study 25336333 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² daily for 5 days
Number of subjects: 149
Study 25336333 — intervention group
Group type: COMPARATOR
Intervention: Decitabine 20 mg/m² daily for 5 days plus oral valproic acid 50 mg/kg daily for 7 days
Number of subjects: 149
Study 22451457 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression stockings (MCS; 15-20 mmHg)
Number of subjects: 108
Study 22451457 — intervention group
Group type: COMPARATOR
Intervention: No compression treatment
Number of subjects: 108
Study 23270247 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanishneedles leaves group (n=48)
Number of subjects: 96
Study 23270247 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 96
Study 18450530 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (TC)
Number of subjects: 26
Study 18450530 — intervention group
Group type: COMPARATOR
Intervention: Control sutures (non-coated)
Number of subjects: 26
Study 18219769 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique A (stapling after full devascularization and mobilization of the gastric curve)
Number of subjects: 40
Study 18219769 — intervention group
Group type: COMPARATOR
Intervention: Technique B (stapling as soon as the lesser sac is entered)
Number of subjects: 40
Study 18219769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 15277160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cactus pear fruit (250 g fresh fruit pulp)
Number of subjects: 18
Study 15277160 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (75 mg twice daily)
Number of subjects: 18
Study 11998113 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 0
Study 11998113 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter removal (not specified in the abstract)
Number of subjects: 0
Study 9062414 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) immunostaining in primary colorectal tumours
Number of subjects: 134
Study 9062414 — intervention group
Group type: COMPARATOR
Intervention: Normal mucosal tissue levels of TS immunostaining
Number of subjects: 134
Study 8432822 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 278
Study 8432822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 278
Study 8432822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 3318445 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg
Number of subjects: 36
Study 3318445 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg
Number of subjects: 36
Study 30997690 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication intervention
Number of subjects: 97
Study 30997690 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal‐Setting, Planning and Self‐Monitoring (GPS) intervention
Number of subjects: 97
Study 30997690 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 97
Study 28985142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour cherries (500 g daily for 30 days)
Number of subjects: 34
Study 28985142 — intervention group
Group type: COMPARATOR
Intervention: Apples (500 g daily for 30 days)
Number of subjects: 34
Study 28985142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 34
Study 26120851 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive injection risk intervention
Number of subjects: 300
Study 26120851 — intervention group
Group type: COMPARATOR
Intervention: Didactic injection risk intervention
Number of subjects: 300
Study 24854806 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Appearance Comparison Scale-Revised (PACS-R)
Number of subjects: 1176
Study 22370318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 924
Study 22370318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924
Study 20659602 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic prophylaxis (1 capsule of Probaclac Vaginal containing 8 billion CFUs of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus)
Number of subjects: 120
Study 20659602 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 120
Study 18834368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (monthly 1-hour education programme)
Number of subjects: 160
Study 18834368 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 160
Study 15827569 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg intravenously)
Number of subjects: 12
Study 15827569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11978284 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin therapy
Number of subjects: 41
Study 11978284 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin therapy (Control)
Number of subjects: 41
Study 10404444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group GPs received telephonic communication during admission and printed information about care and postdischarge recommendations.
Number of subjects: 60
Study 10404444 — intervention group
Group type: COMPARATOR
Intervention: Control group GPs received standard level of communication.
Number of subjects: 60
Study 10404444 — intervention group
Group type: COMPARATOR
Intervention: Follow-up attendance rates for intervention and control patients.
Number of subjects: 60
Study 8626885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (200 mg every 12 hours) and Propranolol (40 mg every 12 hours)
Number of subjects: 18
Study 8626885 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 18
Study 8626885 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone alone
Number of subjects: 18
Study 2248389 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 64
Study 2248389 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 64
Study 6448025 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% clindamycin hydrochloride hydrate applied twice daily for eight weeks
Number of subjects: 14
Study 6448025 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone applied twice daily for eight weeks
Number of subjects: 14
Study 6448025 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% clindamycin hydrochloride hydrate
Number of subjects: 14
Study 6448025 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 14
Study 30931484 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation programme with education and physical training
Number of subjects: 58
Study 30931484 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 58
Study 28261906 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-piece implant with a progressive platform widening and a platform switching connection (SP)
Number of subjects: 47
Study 28261906 — intervention group
Group type: COMPARATOR
Intervention: One-piece implant with a machined collar (TG)
Number of subjects: 47
Study 28261906 — intervention group
Group type: COMPARATOR
Intervention: Control (TG)
Number of subjects: 47
Study 28261906 — intervention group
Group type: EXPERIMENTAL
Intervention: Test (SP)
Number of subjects: 47
Study 26432067 — intervention group
Group type: EXPERIMENTAL
Intervention: FMISO-PET assessment during radiochemotherapy
Number of subjects: 16
Study 23271350 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP technique using a soft mesh with a memory ring
Number of subjects: 0
Study 23271350 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein method
Number of subjects: 0
Study 23271350 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP technique
Number of subjects: 0
Study 21555700 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with standard oncology care
Number of subjects: 151
Study 21555700 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study 19752419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg intravitreal triamcinolone
Number of subjects: 271
Study 19752419 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg intravitreal triamcinolone
Number of subjects: 271
Study 19752419 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 271
Study 19752419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg vs 4‐mg intravitreal triamcinolone
Number of subjects: 271
Study 19752419 — intervention group
Group type: COMPARATOR
Intervention: Observation and 1‐mg intravitreal triamcinolone
Number of subjects: 271
Study 17317080 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support
Number of subjects: 463
Study 17317080 — intervention group
Group type: COMPARATOR
Intervention: Printed brochure
Number of subjects: 463
Study 17317080 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 463
Study 15537905 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of anti-interleukin-12 per kilogram
Number of subjects: 79
Study 15537905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 11340321 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol concentrations in erythrocyte membranes
Number of subjects: 0
Study 11340321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of alpha-tocopherol in erythrocyte membranes to alpha-tocopherol in plasma
Number of subjects: 0
Study 11340321 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherolquinone/alpha-tocopherol ratio in plasma and erythrocyte membranes
Number of subjects: 0
Study 9773840 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding regimen (early-continuous, early-bolus)
Number of subjects: 132
Study 9773840 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal steroid administration
Number of subjects: 132
Study 9773840 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of human milk
Number of subjects: 132
Study 9773840 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding
Number of subjects: 132
Study 7826790 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife top‐up doses of 0.25% bupivacaine 10 ml
Number of subjects: 30
Study 7826790 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% bupivacaine 10 ml h‐1
Number of subjects: 30
Study 7826790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA) with self‐administered 3‐ml bolus doses of 0.25% bupivacaine
Number of subjects: 30
Study 2899977 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 80
Study 2899977 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 80
Study 2899977 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 80
Study 2899977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30296635 — intervention group
Group type: EXPERIMENTAL
Intervention: UHCE approach (preventive multidimensional health assessment and coordinated care-pathways)
Number of subjects: 1844
Study 29798443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo Leaves Soft-gel Capsule and Qiangli Dingxuan tablets (Drug group)
Number of subjects: 93
Study 29798443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation gymnastics (Group C)
Number of subjects: 93
Study 29798443 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 93
Study 24856939 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity stimulation program involving counselling through motivational interviewing, home-based physiotherapy, and 4 months of fitness training.
Number of subjects: 49
Study 24856939 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity stimulation program
Number of subjects: 49
Study 24856939 — intervention group
Group type: COMPARATOR
Intervention: usual paediatric physiotherapy
Number of subjects: 49
Study 22298804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotreatment with pegvisomant (15‐30 mg twice a week) and SA (half the usual dosage)
Number of subjects: 18
Study 22298804 — intervention group
Group type: COMPARATOR
Intervention: SA monotherapy
Number of subjects: 18
Study 20472532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 0
Study 20472532 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 0
Study 20472532 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 0
Study 19356426 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic heart rate control (oral and intravenous beta-blockade for a target heart rate ≤60 beats/min) in single-source CT
Number of subjects: 200
Study 19356426 — intervention group
Group type: COMPARATOR
Intervention: No premedication in single-source CT
Number of subjects: 200
Study 19356426 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic heart rate control in dual-source CT
Number of subjects: 200
Study 19356426 — intervention group
Group type: COMPARATOR
Intervention: No premedication in dual-source CT
Number of subjects: 200
Study 19356426 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic heart rate control in single-source CT
Number of subjects: 200
Study 15161787 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/day)
Number of subjects: 74
Study 15161787 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (1,500 mg/day)
Number of subjects: 74
Study 15161787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study 11578882 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg/min for induction and intubation; decreased to 0.25 microg/kg/min after intubation)
Number of subjects: 2438
Study 11578882 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (administered according to anesthesiologists' usual practice)
Number of subjects: 2438
Study 9768439 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 51
Study 9768439 — intervention group
Group type: COMPARATOR
Intervention: Renal patients
Number of subjects: 51
Study 7816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution of the vehicle with benzyl alcohol saline (BAS)
Number of subjects: 0
Study 7816293 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 0
Study 7816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.1 ml of the vehicle
Number of subjects: 0
Study 7816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.33 ml of the vehicle
Number of subjects: 0
Study 7816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Making the vehicle iso-osmotic
Number of subjects: 0
Study 3046812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 186
Study 3046812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 30946270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-eccentric training
Number of subjects: 41
Study 30946270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-concentric training
Number of subjects: 41
Study 30946270 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-eccentric training
Number of subjects: 41
Study 30946270 — intervention group
Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 41
Study 30946270 — intervention group
Group type: EXPERIMENTAL
Intervention: All training modalities
Number of subjects: 41
Study 30119986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 98
Study 30119986 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolone and trimethoprim-sulfamethoxazole
Number of subjects: 98
Study 30119986 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 98
Study 30119986 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 98
Study 30119986 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 98
Study 30119986 — intervention group
Group type: COMPARATOR
Intervention: Cefdinir
Number of subjects: 98
Study 28793916 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually targeted manual-based vocational rehabilitation (VR) provided by a specialized Brain Injury Centre
Number of subjects: 84
Study 28793916 — intervention group
Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation (usual care) provided by the municipalities
Number of subjects: 84
Study 26004880 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 121
Study 24125438 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®‐TB Gold In‐Tube test (QFT‐GIT)
Number of subjects: 362
Study 24125438 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 362
Study 21353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Itch nocebo (high expectations for itch)
Number of subjects: 0
Study 21353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain nocebo (high expectations for pain)
Number of subjects: 0
Study 21353388 — intervention group
Group type: COMPARATOR
Intervention: Itch nocebo control (low expectations for itch)
Number of subjects: 0
Study 21353388 — intervention group
Group type: COMPARATOR
Intervention: Pain nocebo control (low expectations for pain)
Number of subjects: 0
Study 21353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Itch placebo (verbal suggestions for placebo effect on itch)
Number of subjects: 0
Study 21353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain placebo (verbal suggestions for placebo effect on pain)
Number of subjects: 0
Study 21353388 — intervention group
Group type: COMPARATOR
Intervention: Itch placebo control (neutral suggestions)
Number of subjects: 0
Study 21353388 — intervention group
Group type: COMPARATOR
Intervention: Pain placebo control (neutral suggestions)
Number of subjects: 0
Study 18652318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Tanzhong (CV 17)
Number of subjects: 276
Study 18652318 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese drug Tongru Decoction
Number of subjects: 276
Study 16488840 — intervention group
Group type: EXPERIMENTAL
Intervention: No veiling glare
Number of subjects: 6
Study 16488840 — intervention group
Group type: EXPERIMENTAL
Intervention: Veiling glare comparable to CRT
Number of subjects: 6
Study 16488840 — intervention group
Group type: EXPERIMENTAL
Intervention: Double veiling glare
Number of subjects: 6
Study 16488840 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple veiling glare
Number of subjects: 6
Study 16488840 — intervention group
Group type: EXPERIMENTAL
Intervention: JNDmetrix model analysis
Number of subjects: 6
Study 12900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX group; n = 51)
Number of subjects: 96
Study 12900820 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC group; n = 45)
Number of subjects: 96